
Jul 10, 2026
AI, drug shortages & global regulation
Life sciences organisations operate under some of the most demanding regulatory frameworks in any industry. From the moment a product concept enters development, teams must demonstrate control over processes, data, and decisions — generating evidence that satisfies authorities such as the FDA, EMA, and national competent bodies across global markets.
The software landscape in this domain reflects that complexity. Quality systems govern how deviations, corrective actions, changes, and audits are tracked and closed. Regulatory information management tools structure and route dossiers through submission pipelines, maintaining alignment with evolving standards like IDMP and eCTD. Risk and audit management platforms give organisations visibility over compliance obligations and supplier relationships. Meanwhile, systems that enforce data integrity, electronic signatures, and compliant archiving form the foundation on which all regulated activity depends — ensuring that records are trustworthy, retrievable, and defensible under inspection.
Teams working across these functions often rely on interconnected systems, where a change in one area — a validated process, a submission status, a supplier audit finding — must be traceable and reconciled across the full quality and regulatory landscape.
Software enforcing 21 CFR Part 11 compliance through electronic signatures, audit trails, validation workflows, and data integrity controls across pharma systems.
Software for long-term compliant archiving of laboratory and manufacturing data, with FAIR data principles, audit trails, and FDA/EMA regulatory alignment.
Software for managing quality processes -- CAPA, deviation management, change control, audit management, training, and supplier quality -- in GxP-regulated environments.
Software for creating, managing, publishing, and tracking regulatory submissions and dossiers -- eCTD formatting, IDMP compliance, and global registration workflows.
Platforms for identifying, assessing, and managing quality risks, compliance obligations, and supplier audits across life sciences regulated environments.
CAPA, deviation, and change control records managed in silos make cross-site oversight and inspection readiness nearly impossible.
Manual dossier preparation and formatting across multiple markets creates bottlenecks that delay global registration timelines.
Inadequate electronic records or missing audit trails expose organisations to data integrity findings during regulatory inspections.
Without a structured platform, risk assessments vary in methodology and depth, weakening the organisation's compliance posture.
Tracking which computerised systems are validated, revalidated, or retired becomes unmanageable without dedicated CSV tooling.
Archived laboratory and manufacturing data stored without proper controls risks non-compliance with FDA and EMA retention requirements.
Teams consolidate quality records, audit trails, and validation documentation in advance of FDA or EMA facility inspections.
Regulatory affairs teams use RIM tools to format, track, and publish eCTD dossiers across multiple health authority submissions simultaneously.
A manufacturing deviation triggers a formal workflow covering root cause analysis, CAPA assignment, effectiveness checks, and closure.
Supplier quality processes require documented risk assessments, audit scheduling, and qualification records before materials enter production.
IT and quality teams execute CSV protocols to demonstrate that a new system meets 21 CFR Part 11 requirements before go-live.
Following study closure, regulated data must be archived in a compliant, retrievable format aligned with applicable retention obligations.



Manufacturing execution and process data are subject to the same GxP quality and compliance controls managed here.
Laboratory systems often require CSV validation and generate GxP records that fall within quality and data integrity frameworks.
Regulatory data standards directly inform submission formatting and IDMP compliance within regulatory information management workflows.
Pharmacovigilance and safety reporting intersect closely with regulatory submission pipelines and quality documentation obligations.
Clinical trial oversight generates regulated records — protocols, deviations, audit trails — that feed into quality and regulatory systems.

Jul 10, 2026
AI, drug shortages & global regulation

Jul 9, 2026
Getting ready for the EU AI Act? MDIA’s session has you covered

Jul 7, 2026
MDUFA VI Draft Commitment Letter Includes Faster Pre-Submission Lane, Expanded AI Commitments

Jul 3, 2026
VEEV - AI-Powered Veeva Systems Poised for Solid Growth Amid Regulatory Stability

Jul 3, 2026
As India expands QR tracking, pharma industry looks to AI for quality

Jul 2, 2026
Update: AI-Enabled Medical Devices and IVDs Confirmed as “High-Risk”